Evangelos Messaris, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colectomy | 26 | 2023 | 683 | 5.940 |
Why?
|
| Rectal Neoplasms | 9 | 2023 | 1206 | 2.890 |
Why?
|
| Colorectal Surgery | 6 | 2022 | 128 | 2.740 |
Why?
|
| Ileostomy | 8 | 2023 | 119 | 2.190 |
Why?
|
| Crohn Disease | 11 | 2022 | 2303 | 2.170 |
Why?
|
| Laparoscopy | 12 | 2023 | 2151 | 2.160 |
Why?
|
| Colitis, Ulcerative | 10 | 2023 | 1912 | 2.130 |
Why?
|
| Digestive System Surgical Procedures | 5 | 2022 | 576 | 1.710 |
Why?
|
| Rectum | 6 | 2020 | 904 | 1.490 |
Why?
|
| Rectal Diseases | 3 | 2021 | 143 | 1.380 |
Why?
|
| Colonic Diseases | 3 | 2021 | 202 | 1.350 |
Why?
|
| Colonic Neoplasms | 6 | 2023 | 2541 | 1.340 |
Why?
|
| Anastomotic Leak | 6 | 2023 | 162 | 1.170 |
Why?
|
| Sigmoid Diseases | 3 | 2015 | 50 | 1.130 |
Why?
|
| Ileum | 4 | 2022 | 565 | 1.100 |
Why?
|
| Postoperative Complications | 24 | 2023 | 15295 | 1.090 |
Why?
|
| Surgical Stapling | 2 | 2022 | 97 | 1.030 |
Why?
|
| Rectal Prolapse | 1 | 2024 | 30 | 0.940 |
Why?
|
| Hypoalbuminemia | 1 | 2023 | 87 | 0.870 |
Why?
|
| Diverticulitis | 2 | 2015 | 171 | 0.860 |
Why?
|
| Diverticulitis, Colonic | 2 | 2022 | 128 | 0.860 |
Why?
|
| Sepsis | 10 | 2013 | 2593 | 0.850 |
Why?
|
| Hernia, Ventral | 2 | 2015 | 176 | 0.850 |
Why?
|
| Umbilicus | 1 | 2022 | 41 | 0.820 |
Why?
|
| Anastomosis, Surgical | 8 | 2022 | 987 | 0.810 |
Why?
|
| Proctocolectomy, Restorative | 6 | 2023 | 189 | 0.780 |
Why?
|
| Fecal Incontinence | 1 | 2024 | 239 | 0.780 |
Why?
|
| Suture Techniques | 2 | 2022 | 798 | 0.750 |
Why?
|
| Protein C | 3 | 2010 | 138 | 0.700 |
Why?
|
| Intra-Abdominal Fat | 2 | 2015 | 591 | 0.690 |
Why?
|
| Gastrointestinal Agents | 3 | 2022 | 494 | 0.690 |
Why?
|
| Colon | 4 | 2022 | 1772 | 0.680 |
Why?
|
| Colorectal Neoplasms | 6 | 2024 | 6773 | 0.680 |
Why?
|
| Ileocecal Valve | 1 | 2018 | 21 | 0.670 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 2728 | 0.650 |
Why?
|
| Retrospective Studies | 43 | 2023 | 77449 | 0.650 |
Why?
|
| Preoperative Care | 5 | 2021 | 2250 | 0.630 |
Why?
|
| Venous Thromboembolism | 4 | 2022 | 1671 | 0.610 |
Why?
|
| Inflammatory Bowel Diseases | 6 | 2022 | 2425 | 0.570 |
Why?
|
| Biological Factors | 1 | 2017 | 164 | 0.560 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1061 | 0.520 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 594 | 0.490 |
Why?
|
| Length of Stay | 8 | 2021 | 6309 | 0.480 |
Why?
|
| Specialization | 1 | 2019 | 777 | 0.470 |
Why?
|
| Apoptosis | 8 | 2013 | 9727 | 0.460 |
Why?
|
| 5'-Nucleotidase | 1 | 2014 | 160 | 0.460 |
Why?
|
| Peripheral Nerves | 1 | 2017 | 466 | 0.460 |
Why?
|
| Colonic Polyps | 1 | 2018 | 542 | 0.460 |
Why?
|
| Bupivacaine | 1 | 2017 | 411 | 0.450 |
Why?
|
| Clostridium Infections | 2 | 2017 | 548 | 0.430 |
Why?
|
| Abdominal Abscess | 1 | 2014 | 154 | 0.430 |
Why?
|
| Humans | 85 | 2024 | 744343 | 0.430 |
Why?
|
| Multiple Organ Failure | 1 | 2014 | 390 | 0.420 |
Why?
|
| Ileitis | 1 | 2011 | 44 | 0.410 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 3778 | 0.390 |
Why?
|
| Aged | 37 | 2024 | 163280 | 0.390 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 391 | 0.390 |
Why?
|
| Male | 56 | 2023 | 350118 | 0.370 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 1405 | 0.370 |
Why?
|
| Middle Aged | 44 | 2022 | 213383 | 0.370 |
Why?
|
| Nerve Block | 1 | 2017 | 644 | 0.370 |
Why?
|
| Dehydration | 1 | 2012 | 234 | 0.370 |
Why?
|
| Rats, Wistar | 9 | 2010 | 1901 | 0.360 |
Why?
|
| Postoperative Period | 3 | 2022 | 1842 | 0.350 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 985 | 0.350 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2014 | 794 | 0.350 |
Why?
|
| Colostomy | 2 | 2022 | 99 | 0.340 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 1972 | 0.340 |
Why?
|
| Adult | 41 | 2024 | 214055 | 0.340 |
Why?
|
| Anus Neoplasms | 1 | 2013 | 332 | 0.340 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2013 | 604 | 0.330 |
Why?
|
| Neoplasm Staging | 9 | 2023 | 11031 | 0.330 |
Why?
|
| Immunologic Factors | 1 | 2018 | 1580 | 0.330 |
Why?
|
| Databases, Factual | 6 | 2023 | 7729 | 0.320 |
Why?
|
| Colon, Sigmoid | 2 | 2022 | 120 | 0.320 |
Why?
|
| General Surgery | 2 | 2020 | 1636 | 0.320 |
Why?
|
| Lipopolysaccharides | 2 | 2013 | 2216 | 0.310 |
Why?
|
| Hernia, Inguinal | 1 | 2010 | 210 | 0.300 |
Why?
|
| Pancreatitis | 1 | 2014 | 1092 | 0.300 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 4420 | 0.300 |
Why?
|
| Cecum | 3 | 2018 | 237 | 0.300 |
Why?
|
| Hospital Costs | 1 | 2014 | 985 | 0.300 |
Why?
|
| Colonic Pouches | 2 | 2019 | 121 | 0.290 |
Why?
|
| Female | 49 | 2022 | 380194 | 0.290 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 1643 | 0.290 |
Why?
|
| Colitis | 2 | 2012 | 1170 | 0.280 |
Why?
|
| Patient Compliance | 1 | 2017 | 2684 | 0.280 |
Why?
|
| Cytochromes c | 5 | 2009 | 180 | 0.280 |
Why?
|
| bcl-2-Associated X Protein | 6 | 2009 | 295 | 0.280 |
Why?
|
| Gelsolin | 1 | 2007 | 190 | 0.280 |
Why?
|
| Treatment Outcome | 16 | 2024 | 63114 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2009 | 1434 | 0.270 |
Why?
|
| Patient Admission | 2 | 2013 | 1380 | 0.270 |
Why?
|
| Propensity Score | 3 | 2019 | 1781 | 0.270 |
Why?
|
| Kidney Tubules | 1 | 2008 | 488 | 0.270 |
Why?
|
| Leukocytes | 1 | 2014 | 2043 | 0.270 |
Why?
|
| Caspase 8 | 4 | 2008 | 195 | 0.270 |
Why?
|
| Risk Factors | 15 | 2024 | 72290 | 0.260 |
Why?
|
| Fibrinolysis | 1 | 2006 | 322 | 0.260 |
Why?
|
| Aged, 80 and over | 17 | 2022 | 57776 | 0.250 |
Why?
|
| Statistics, Nonparametric | 5 | 2022 | 2886 | 0.250 |
Why?
|
| Endotoxemia | 1 | 2006 | 207 | 0.250 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 1540 | 0.250 |
Why?
|
| Patient Readmission | 4 | 2015 | 3114 | 0.250 |
Why?
|
| Gastric Mucosa | 1 | 2007 | 599 | 0.230 |
Why?
|
| Colonoscopy | 2 | 2022 | 1367 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 6364 | 0.230 |
Why?
|
| Deferoxamine | 1 | 2004 | 151 | 0.230 |
Why?
|
| Cohort Studies | 10 | 2021 | 40561 | 0.220 |
Why?
|
| Free Radical Scavengers | 1 | 2004 | 216 | 0.220 |
Why?
|
| Iron Chelating Agents | 1 | 2004 | 139 | 0.220 |
Why?
|
| Purkinje Cells | 1 | 2004 | 224 | 0.220 |
Why?
|
| Regression Analysis | 2 | 2024 | 6459 | 0.220 |
Why?
|
| Disease Models, Animal | 6 | 2014 | 18029 | 0.210 |
Why?
|
| Swine | 2 | 2022 | 5917 | 0.210 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 7659 | 0.210 |
Why?
|
| Neutrophils | 2 | 2014 | 3719 | 0.210 |
Why?
|
| Choroid Plexus | 1 | 2004 | 231 | 0.200 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2007 | 612 | 0.200 |
Why?
|
| Microfilament Proteins | 1 | 2007 | 1152 | 0.200 |
Why?
|
| Lymphatic Metastasis | 4 | 2018 | 2924 | 0.190 |
Why?
|
| Multivariate Analysis | 6 | 2022 | 12245 | 0.190 |
Why?
|
| Young Adult | 10 | 2020 | 56430 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 3616 | 0.180 |
Why?
|
| Blood Coagulation | 1 | 2006 | 1127 | 0.180 |
Why?
|
| Accreditation | 1 | 2023 | 450 | 0.180 |
Why?
|
| Jejunum | 1 | 2022 | 480 | 0.180 |
Why?
|
| Intensive Care Units | 1 | 2013 | 3679 | 0.180 |
Why?
|
| Rats | 10 | 2010 | 24260 | 0.170 |
Why?
|
| Industry | 1 | 2022 | 365 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 9239 | 0.170 |
Why?
|
| Constipation | 1 | 2024 | 546 | 0.170 |
Why?
|
| Recurrence | 4 | 2022 | 8340 | 0.170 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2010 | 643 | 0.170 |
Why?
|
| Inflammation | 3 | 2022 | 10638 | 0.160 |
Why?
|
| Quality Improvement | 4 | 2023 | 3749 | 0.150 |
Why?
|
| Cytokines | 2 | 2010 | 7322 | 0.150 |
Why?
|
| Bibliometrics | 1 | 2021 | 339 | 0.150 |
Why?
|
| Conflict of Interest | 1 | 2022 | 544 | 0.140 |
Why?
|
| Abdominal Muscles | 1 | 2017 | 166 | 0.140 |
Why?
|
| Minority Groups | 1 | 2024 | 1223 | 0.140 |
Why?
|
| Cicatrix | 1 | 2022 | 764 | 0.140 |
Why?
|
| Pennsylvania | 1 | 2017 | 613 | 0.130 |
Why?
|
| Hernia, Abdominal | 2 | 2014 | 53 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 12072 | 0.130 |
Why?
|
| Survival Rate | 6 | 2018 | 12788 | 0.130 |
Why?
|
| Survival Analysis | 7 | 2017 | 10252 | 0.130 |
Why?
|
| Genes, bcl-2 | 3 | 2004 | 122 | 0.130 |
Why?
|
| Intestinal Obstruction | 2 | 2011 | 424 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2021 | 950 | 0.130 |
Why?
|
| Adolescent | 10 | 2020 | 85781 | 0.130 |
Why?
|
| Animals | 15 | 2022 | 168757 | 0.130 |
Why?
|
| United States | 7 | 2024 | 69872 | 0.130 |
Why?
|
| Random Allocation | 3 | 2010 | 2429 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 20129 | 0.130 |
Why?
|
| Emergencies | 2 | 2019 | 1170 | 0.120 |
Why?
|
| Patient Selection | 2 | 2010 | 4215 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 3508 | 0.120 |
Why?
|
| Collagen | 1 | 2022 | 2689 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 15076 | 0.120 |
Why?
|
| Prognosis | 8 | 2018 | 29063 | 0.120 |
Why?
|
| Patients' Rooms | 1 | 2014 | 63 | 0.120 |
Why?
|
| Registries | 4 | 2020 | 8089 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 39050 | 0.110 |
Why?
|
| Liposomes | 1 | 2017 | 759 | 0.110 |
Why?
|
| Caspases | 3 | 2009 | 928 | 0.110 |
Why?
|
| Body Fat Distribution | 1 | 2014 | 244 | 0.110 |
Why?
|
| Mental Health | 2 | 2024 | 3019 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2282 | 0.110 |
Why?
|
| Obesity | 1 | 2014 | 12745 | 0.100 |
Why?
|
| Adenoma | 1 | 2022 | 2174 | 0.100 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 197 | 0.100 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 545 | 0.100 |
Why?
|
| Time Factors | 6 | 2021 | 40075 | 0.100 |
Why?
|
| Hippocampus | 1 | 2004 | 3675 | 0.100 |
Why?
|
| Hospital Charges | 1 | 2014 | 362 | 0.100 |
Why?
|
| Gene Expression | 2 | 2004 | 7799 | 0.100 |
Why?
|
| Accidents, Traffic | 2 | 2008 | 819 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3870 | 0.100 |
Why?
|
| Intestinal Fistula | 1 | 2011 | 140 | 0.090 |
Why?
|
| Camptothecin | 1 | 2013 | 576 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 625 | 0.090 |
Why?
|
| Ischemia | 2 | 2011 | 1907 | 0.090 |
Why?
|
| Seroma | 1 | 2010 | 71 | 0.090 |
Why?
|
| Flow Cytometry | 3 | 2010 | 5974 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 35421 | 0.090 |
Why?
|
| Cellulitis | 1 | 2011 | 206 | 0.090 |
Why?
|
| Organ Size | 1 | 2015 | 2252 | 0.090 |
Why?
|
| Intestines | 2 | 2011 | 1924 | 0.090 |
Why?
|
| Calcitonin | 1 | 2011 | 336 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2012 | 676 | 0.090 |
Why?
|
| Mice | 3 | 2022 | 81183 | 0.090 |
Why?
|
| Tissue Adhesions | 3 | 2007 | 235 | 0.090 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 662 | 0.080 |
Why?
|
| Ligation | 1 | 2010 | 453 | 0.080 |
Why?
|
| Remission Induction | 1 | 2014 | 2386 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15540 | 0.080 |
Why?
|
| Keratin-18 | 1 | 2008 | 39 | 0.080 |
Why?
|
| Cytoprotection | 1 | 2009 | 210 | 0.080 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2008 | 226 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2019 | 2212 | 0.080 |
Why?
|
| Logistic Models | 2 | 2014 | 13408 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2014 | 1530 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 11366 | 0.080 |
Why?
|
| Catheterization | 2 | 2005 | 1470 | 0.080 |
Why?
|
| Abscess | 1 | 2011 | 607 | 0.080 |
Why?
|
| Surgical Mesh | 1 | 2010 | 276 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2012 | 526 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2013 | 956 | 0.070 |
Why?
|
| Operating Rooms | 1 | 2014 | 817 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 2716 | 0.070 |
Why?
|
| Protein Precursors | 1 | 2011 | 1154 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 1783 | 0.070 |
Why?
|
| Neurons | 2 | 2009 | 9338 | 0.070 |
Why?
|
| Drug Costs | 1 | 2014 | 1105 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2017 | 2063 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2017 | 9849 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 1613 | 0.070 |
Why?
|
| bcl-X Protein | 1 | 2007 | 411 | 0.070 |
Why?
|
| Multiple Trauma | 1 | 2008 | 367 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2021 | 3309 | 0.060 |
Why?
|
| Research Design | 1 | 2001 | 5987 | 0.060 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 253 | 0.060 |
Why?
|
| Peritoneal Cavity | 1 | 2005 | 148 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 1790 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2008 | 2645 | 0.060 |
Why?
|
| Risk | 1 | 2017 | 9687 | 0.060 |
Why?
|
| Probability | 1 | 2010 | 2505 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2503 | 0.060 |
Why?
|
| Motor Vehicles | 1 | 2006 | 268 | 0.060 |
Why?
|
| Medicare | 1 | 2022 | 6566 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2969 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 1799 | 0.060 |
Why?
|
| Anxiety | 1 | 2018 | 4297 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2023 | 53288 | 0.050 |
Why?
|
| Genes, fos | 1 | 2003 | 183 | 0.050 |
Why?
|
| Comorbidity | 1 | 2017 | 10388 | 0.050 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2002 | 7 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2013 | 4217 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2001 | 768 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2017 | 4599 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 12804 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2017 | 21746 | 0.050 |
Why?
|
| Peritoneal Diseases | 1 | 2002 | 75 | 0.050 |
Why?
|
| Linear Models | 2 | 2022 | 5952 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 25043 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 3674 | 0.050 |
Why?
|
| Spermatic Cord | 1 | 2000 | 25 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2003 | 755 | 0.050 |
Why?
|
| Spleen | 1 | 2006 | 2362 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 4554 | 0.040 |
Why?
|
| Genital Neoplasms, Male | 1 | 2000 | 74 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2004 | 1539 | 0.040 |
Why?
|
| Radiology | 1 | 2014 | 2100 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 20947 | 0.040 |
Why?
|
| Liver | 2 | 2006 | 7474 | 0.040 |
Why?
|
| Germinoma | 1 | 2000 | 133 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2001 | 407 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6538 | 0.040 |
Why?
|
| Medical Audit | 1 | 2020 | 467 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 3479 | 0.040 |
Why?
|
| Depression | 1 | 2018 | 7766 | 0.040 |
Why?
|
| Greece | 3 | 2006 | 344 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2003 | 726 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2001 | 1588 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2014 | 12720 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2023 | 1198 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2006 | 3200 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 13695 | 0.030 |
Why?
|
| Sex Factors | 1 | 2010 | 10397 | 0.030 |
Why?
|
| Age Factors | 2 | 2010 | 18370 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 990 | 0.030 |
Why?
|
| Necrosis | 2 | 2011 | 1643 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7181 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 11524 | 0.030 |
Why?
|
| Injury Severity Score | 2 | 2008 | 1014 | 0.030 |
Why?
|
| Language | 1 | 2022 | 1471 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 2400 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2001 | 1199 | 0.030 |
Why?
|
| Program Development | 1 | 2019 | 1316 | 0.030 |
Why?
|
| Polyurethanes | 2 | 2005 | 107 | 0.030 |
Why?
|
| Melanoma | 2 | 2002 | 5510 | 0.030 |
Why?
|
| Bystander Effect | 1 | 2013 | 81 | 0.030 |
Why?
|
| Polytetrafluoroethylene | 2 | 2005 | 233 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2000 | 1381 | 0.030 |
Why?
|
| Silicones | 2 | 2005 | 250 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 12354 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 408 | 0.030 |
Why?
|
| Neoplasms | 1 | 2001 | 21683 | 0.030 |
Why?
|
| Leucovorin | 1 | 2013 | 628 | 0.030 |
Why?
|
| Mitochondria | 1 | 2004 | 3520 | 0.020 |
Why?
|
| Trauma Centers | 2 | 2006 | 890 | 0.020 |
Why?
|
| Myocardium | 1 | 2004 | 4776 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2000 | 1333 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2000 | 2948 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2002 | 2020 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2003 | 2282 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2022 | 23338 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2013 | 1619 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2011 | 306 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 3086 | 0.020 |
Why?
|
| Kidney | 1 | 2004 | 7186 | 0.020 |
Why?
|
| Turkey | 1 | 2008 | 237 | 0.020 |
Why?
|
| Hospitals | 1 | 2021 | 3952 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2019 | 3743 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 1706 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 1583 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 1988 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3701 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 1654 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 1206 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2008 | 570 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 4034 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 9438 | 0.020 |
Why?
|
| Motorcycles | 1 | 2006 | 44 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 3557 | 0.020 |
Why?
|
| Intestinal Neoplasms | 1 | 2007 | 319 | 0.020 |
Why?
|
| Reticulocyte Count | 1 | 2003 | 37 | 0.010 |
Why?
|
| Abdominal Injuries | 1 | 2006 | 352 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6895 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 5686 | 0.010 |
Why?
|
| Polyvinyl Chloride | 1 | 2002 | 34 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 370 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 26385 | 0.010 |
Why?
|
| Child | 1 | 2010 | 77709 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2001 | 103 | 0.010 |
Why?
|
| Hematocrit | 1 | 2003 | 636 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2001 | 242 | 0.010 |
Why?
|
| Astrocytes | 1 | 2009 | 1270 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 10943 | 0.010 |
Why?
|
| Pyridines | 1 | 2013 | 2825 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2013 | 2942 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 1364 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 2003 | 379 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2000 | 8863 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2002 | 1681 | 0.010 |
Why?
|
| Bleomycin | 1 | 2000 | 512 | 0.010 |
Why?
|
| Etoposide | 1 | 2000 | 641 | 0.010 |
Why?
|
| Walking | 1 | 2006 | 1180 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2013 | 3481 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2002 | 1150 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 1534 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8428 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2003 | 1301 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 16689 | 0.010 |
Why?
|
| Models, Biological | 1 | 2013 | 9583 | 0.010 |
Why?
|
| Cause of Death | 1 | 2006 | 3584 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 1641 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2000 | 1770 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2008 | 5317 | 0.010 |
Why?
|
| Cisplatin | 1 | 2000 | 1662 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 6622 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 2951 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 23403 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 12026 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 8642 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 2734 | 0.000 |
Why?
|
| Disease Progression | 1 | 2002 | 13284 | 0.000 |
Why?
|